Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Cryptyx Bioscience
AddedFeb 18, 2024
UpdatedJun 18, 2026
Cryptyx Bioscience

Cryptyx Bioscience

Angel

Cryptyx Bioscience: A biopharmaceutical platform unlocking therapeutic potential in bacteria.

HQ
Princeton, NJ, US
Founded
2020
Overview
Compare
Fundraising
Employees
Website

Cryptyx Bioscience, a biopharmaceutical platform company, was founded with the mission to unlock the therapeutic potential of bacteria through a genetics-free, cloning-free approach. The company's core vision is to combat diseases by discovering hidden natural products encoded in bacteria. Cryptyx's innovative drug discovery platform activates silent biosynthetic gene clusters in bacteria, providing a rapid and efficient method to uncover potential therapeutic leads that traditional technologies cannot access. Their market focus includes developing novel therapies for various diseases by harnessing bacterial small molecules.

Notable figures affiliated with Cryptyx Bioscience include leading scientists and industry experts in microbiology and drug discovery. The company has attracted significant interest from investors focused on groundbreaking biopharmaceutical innovations. Key achievements include the successful activation of previously inaccessible biosynthetic gene clusters and the identification of new therapeutic compounds. Cryptyx Bioscience's impact lies in its potential to revolutionize drug discovery, offering new avenues for treating diseases with novel, bacteria-derived therapies.

Cryptyx Bioscience - Quick Facts

When was Cryptyx Bioscience founded?

Cryptyx Bioscience was founded in 2020.

Where is Cryptyx Bioscience's headquarters located?

Cryptyx Bioscience's headquarters is located in Princeton, NJ, US.

When was Cryptyx Bioscience's last funding round?

Cryptyx Bioscience's most recent funding round was for $256k (USD) in March 2022.

How much has Cryptyx Bioscience raised to-date?

As of Mar 21, 2022, Cryptyx Bioscience has raised a total of $256k (USD).

How many employees does Cryptyx Bioscience have?

Cryptyx Bioscience has 1 employee as of Feb 4, 2024.

Cryptyx Bioscience - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Drug Discovery
Tags
  • Platform
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 15 more industry codes
NAICS
  • 513200Software Publishers
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 510000Information
  • 620000Health Care and Social Assistance
  • 513000Publishing Industries
  • 541700Scientific Research and Development Services
  • 513210Software Publishers
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8000Health Services
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8730Research, Development, And Testing Services
  • 7372Prepackaged Software
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
  • 8731Commercial Physical and Biological Research